Enveda raises another $150M, claims unicorn status

BOULDER — Boulder-based Enveda Biosciences, which uses machine learning to discover naturally occurring drug compounds, recently closed a $150 million Series D funding round led by Premji Invest.

The company has raised a total of $517 million and now claims a $1 billion unicorn valuation.

“Enveda is proving that it’s possible to generate novel and first-in-class small molecule therapeutics at an unprecedented speed, scale, and efficiency,” Premji Invest principal Akshay Rai said in a prepared statement. “We believe there is a large unexplored search space for novel medicines, and Enveda has built the platform to translate life’s chemistry into treatments that could be transformative for millions of patients across the globe. This team is turning breakthrough science into medicines at a pace that is exceptionally rare, and are on their way to building what could be an industry-defining company.”

The roughly 5-year-old Enveda, which wrapped up a $119 million Series B fundraising round last year and a roughly $150 million Series C, had about 250 employees across the globe, including at Enveda’s Asian headquarters in Hyderabad, India, as of late 2024.

The company’s North American operations are based out of a 60,000-square-foot facility in Boulder’s Flatiron Park business campus.

Share on Facebook on LinkedIn